The transition to continuous bioprocessing in the biopharmaceutical industry is gradually unfolding. While uptake has been measured, certain processes are leading the charge. With the biopharmaceutical sector boasting annual sales exceeding $200 billion, the need for manufacturing innovation has never been clearer.
Despite the complexity inherent in biotherapeutics, the fundamental manufacturing processes have remained stagnant for years, unlike other industries that have embraced continuous manufacturing. This shift promises improved efficiency and cost-effectiveness. However, the technology to enable large-scale continuous manufacturing has only recently matured. A survey by BioPlan Associates highlighted that many industry stakeholders consider the advancement of continuous bioprocessing technologies for downstream production as crucial.
Traditional Batch Processing vs. Continuous Processing
Traditionally, biopharmaceuticals have relied on batch processing, where individual unit operations are performed sequentially. In contrast, continuous processing allows each step to occur simultaneously, moving products to the next phase as they are completed. This method can significantly enhance cost-effectiveness and reduce infrastructure needs. Despite its potential, the widespread adoption of continuous bioprocessing has been gradual, with perfusion processes emerging as notable exceptions.
Perceptions Impacting Adoption
The slow uptake of continuous processing can be attributed to several perception-related issues. Although continuous processing offers numerous advantages—like reduced costs, enhanced productivity, and improved product quality—many manufacturers remain hesitant. The familiarity and proven reliability of batch processing make it a safer choice for many. Concerns surrounding contamination risks, process complexity, and control challenges dominate perceptions of continuous methods.
Recent advancements have made continuous bioprocessing less complex and more user-friendly, yet these perceptions linger. The industry must address these outdated views to facilitate broader acceptance of continuous methodologies.
Regulatory Landscape and Challenges
The highly regulated nature of the biopharmaceutical industry contributes to the slow adoption of continuous bioprocessing. Regulatory agencies like the FDA are cautiously optimistic about continuous methods, recognizing their potential for better process control and product quality. However, few manufacturers are willing to pioneer these changes, preferring to stick with established batch-fed technologies. Compounding this reluctance are the challenges associated with integrating new technologies, including the lack of practical knowledge, precedents, and cost-effective equipment.
Current State of Continuous Bioprocessing
To date, the adoption of continuous bioprocessing has primarily been limited to a few unit processes and smaller-scale perfusion methods. BioPlan’s annual report indicates a steady interest in evaluating continuous bioprocessing technologies, particularly in upstream processes—evidenced by around 31% of respondents actively testing upstream technologies. However, downstream operations have not seen similar enthusiasm, which remains a significant gap.
Innovations Driving Change
Several companies are developing technologies to facilitate continuous bioprocessing. For instance, Pall Corporation introduced the Cadence BioSMB Process system, a scalable multi-column chromatography solution. This innovation allows manufacturers to transition into continuous purification, addressing some of the pressing downstream needs.
Additionally, Novartis has partnered with MIT to establish the Novartis-MIT Center for Continuous Manufacturing. This collaboration aims to create new continuous manufacturing technologies, with Novartis committing $65 million to the initiative over ten years. Such partnerships highlight a growing commitment to transforming pharmaceutical production.
Capacity Constraints and Industry Challenges
Capacity constraints remain a significant concern within the biopharmaceutical industry. The latest BioPlan report notes that nearly 30% of respondents reported experiencing severe or significant constraints at the commercial manufacturing level. The industry’s ability to meet increasing demand hinges on addressing these issues, with facility constraints, analytical testing, and staffing shortages identified as primary contributors to potential bottlenecks.
Interestingly, the need for improved continuous bioprocessing technologies ranked high among factors that could mitigate future capacity constraints. Despite the acknowledgment of these needs, the actual adoption of continuous methods, particularly in downstream processes, has not yet gained momentum.
Future Trajectory and Industry Adaptation
While the shift toward continuous bioprocessing has been slow, the trajectory suggests a gradual adoption similar to that of single-use systems. Continuous manufacturing is poised to become the favored approach over time, as ongoing advancements in technology and increasing demand for flexibility and efficiency propel the industry forward. Notable examples, such as Vertex’s Orkambi, which employs continuous manufacturing processes, illustrate the potential for success in this area.
The industry recognizes the importance of continuous bioprocessing, particularly for downstream applications. As early adopters pave the way, the knowledge base will expand, making it easier for others to embrace significant manufacturing changes.
Key Takeaways
- Continuous bioprocessing offers cost savings, flexibility, and improved product quality, yet adoption remains slow due to entrenched perceptions and regulatory concerns.
- Regulatory agencies like the FDA are supportive of continuous methods, recognizing their potential for enhanced process control.
-
Innovations such as the Cadence BioSMB Process system and partnerships like the Novartis-MIT Center for Continuous Manufacturing signal a commitment to advancing continuous technologies.
-
Capacity constraints in manufacturing highlight the urgency for improved continuous bioprocessing solutions, particularly in downstream processes.
-
The gradual acceptance of continuous manufacturing will likely mirror the evolution of single-use systems, ultimately reshaping biopharmaceutical production.
In conclusion, the shift toward continuous bioprocessing is not merely a trend but a necessary evolution in the biopharmaceutical industry. As perceptions evolve and technology matures, the industry stands poised to embrace this transformative approach, enhancing production efficiency and product quality for the future.
Source: www.pharmtech.com